National and Kapodistrian University of Athens
Αξιοποίηση της αλυσιδωτής αντίδρασης της πολυμεράσης (PCR) και της χημειοφωταυγούς ανίχνευσης για τον προσδιορισμό μοριακών δεικτών του καρκίνου του προστάτη σε περιφερικό αίμα
Abstract
dc:descriptionProstate cancer is the most commonly diagnosed neoplasm in men in the Western world. The sensitivity of current staging modalities is inadequate and more than one third of men with clinically localized prostate cancer are found to be understaged at the time of surgery. Recent studies have suggested that both detection and quantification of circulating prostate cancer cells strongly indicate the presence of metastasis.In the present study, the development of two quantitative methods for the mRNA determination of two specific prostate cancer molecular markers, PSA and PSMA, is described. The simultaneous qualitative detection of both PSA and PSMA mRNA messages in peripheral blood is also reported. The aforementioned tests utilize RT-PCR and a chemiluminometric hybridization assay in a microtiter well-based format.For the PSA mRNA quantification assay, the method includes the construction of a recombinant RNA IS that has the same sequence and primer binding sites as PSA mRNA but differs only in a 24-bp segment. A constant amount of RNA IS is added to the cell lysate prior to RNA isolation. Total RNA from a 5-ml venous blood sample is coextracted with PSA-IS RNA and subjected to RT-PCR. Amplified sequences are labeled with biotin through PCR by using a biotinylated upstream primer. Following heat-denaturation, the biotinylated products (PSA and PSA-IS) are hybridized with oligonucleotide-specific probes that are immobilized on separate microtiter wells. Immobilization of probes is achieved by absorption of their conjugates with BSA. The hybrids are measured using AP- labeled streptavidin and a dioxetane chemiluminogenic substrate. The ratio of the luminescence values obtained for the PSA mRNA and the PSA-IS RNA is a linear function of the initial amount of PSA mRNA present in the sample prior to RT-PCR amplification.The same technique for immobilization of probes is used for the development of the PSA/PSMA hybridization assay. Again total RNA from peripheral blood is subjected to RT-PCR, the biotinylated amplified products (PSA and PSMA) are heat denatured and captured on separate microtiter wells coated with probes specific for each PSA and PSMA target DNA. Addition of strepiavidin-conjugated alkaline phosphatase allows the detection of the hybridization products.As with PSA, the quantitation of PSMA mRNA involves the use of a recombinant RNA IS with similar characteristics. A constant amount of PSMA-IS RNA is added in the reverse transcription mixture. Following RT-PCR, the biotinylated amplified DNA products (PSMA and PSMA-IS) are captured on microtiter wells coated with streptavidin. Immobilized products are then allowed to hybridize to specific alkaline phosphatase- conjugated probes. The hybrids are finally detected by the addition of a dioxetane chemiluminogenic AP substate. The ratio of the luminescence values obtained for PSMA mRNA and PSMA-IS mRNA is linearly related to the initial amount of PSMA mRNA in the sample prior to RT-PCR amplification.In addition, the conjugation chemistry for the covalent coupling of oligonucleotides to proteins is described in detail. Since this chemistry involves more than one reaction steps, optimization conditions for each step are also discussed.As implied by their analytical performance, the proposed methods combine high sensitivity and reproducibility with a wide linear range. Validation of the assays using total RNA extracted from LNCaP cells, a prostate cancer-derived cell line, indicated that as low as 0.5 cancer cell equivalents can be detected from a 5 ml blood sample.From the three methods described above, the first two were also applied to clinical samples from both prostate cancer patients and healthy volunteers. Using the PSA mRNA quantification assay, 50% of the samples from patients with prostate cancer gave results above the detection limit. No PSA mRNA was detected in healthy individuals. On the other hand, the simultaneous detection of PSA and PSMA expression in peripheral blood confirmed the notion that the combined PSA/PSMA assay provides greater sensitivity than PSA or PSMA assay alone in detecting circulating prostatic cells.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2003
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Emmanouilidou, Evangelia
- Εμμανουηλίδου, Ευαγγελία
Subjects
dc:subject × 20- Καρκίνος προστάτη
- Ειδικό προστατικό αντιγόνο
- Ειδικό προστατικό μεμβρανικό αντιγόνο
- Αλυσιδωτή αντίδραση πολυμεράσης
- Χημειοφωταύγεια
- Αλκαλική φωσφατάση
- Προϊόντα σύζευξης
- Πλακίδια μικροτιτλοδότησης
- Prostate cancer
- Prostate specific antigen (PSA)
- Prostate specific membrane antigen
- Quantitative RT-PCR
- Chemiluminescence
- Alkaline phosphatase
- Conjugation reaction
- Microtiter wells
- Φυσικές Επιστήμες
- Χημεία
- Natural Sciences
- Chemical Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/21289